Loading clinical trials...
Loading clinical trials...
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Conditions
Interventions
Elranatamab
Iberdomide
Locations
43
United States
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
Coral Gables, Florida, United States
University of Miami Hospital and Clinics Deerfield Beach
Deerfield Beach, Florida, United States
Sylvester Comprehensive Cancer Center- Doral
Doral, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
University of Miami Hospital and Clinics
Miami, Florida, United States
Sylvester Comprehensive Cancer Center Kendall
Miami, Florida, United States
Start Date
February 20, 2024
Primary Completion Date
April 10, 2027
Completion Date
March 9, 2028
Last Updated
April 23, 2026
NCT07249528
NCT06679101
NCT05969860
NCT06057402
NCT06870760
NCT06383143
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions